Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 1Neuroblastoma 1Multiple Endocrine Neoplasia 1Carcinoid Tumor 1Adrenal Gland Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 2Fluorodeoxyglucose F18 2FAPI-46 2pertuzumab 1olaparib 1lutetium Lu 177 dotatate 1Quality of Life 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1Immunotherapy 1Erlotinib Hydrochloride 1Drug Therapy 1Cryosurgery 1Biological Therapy 1(18F)GTP1 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adrenal Gland Neoplasms × pertuzumab × NET × Clear all
NCT00947167 2017-03-03

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Stanford University

Phase 2 Terminated
4 enrolled 5 charts
CNSEndocrineNET

Adrenal Gland Neoplasms, Carcinoid Tumor, Multiple Endocrine Neoplasia, Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡